Evidence map›Paper›PMID 38213818›Full record

ArticleEJC paediatric oncology2023

Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades.

Mohansrinivas Chennakesavalu, Caileigh Pudela, Mark A Applebaum, Sang Mee Lee, Yan Che, Arlene Naranjo, Julie R Park, Samuel L Volchenboum, Tara O Henderson, Susan L Cohn and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJC paediatric oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Mohansrinivas ChennakesavaluPritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Caileigh PudelaMedStar Georgetown University Hospital, Washington, D.C., USA.
Mark A ApplebaumDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
Sang Mee LeeDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
Yan CheDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
Arlene NaranjoChildren's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Julie R ParkSt. Jude Children's Research Hospital, Memphis, TN, USA.
Samuel L VolchenboumDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
Tara O HendersonDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
Susan L CohnDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
Ami V DesaiDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
University of Chicago · USChicago Department of Public Health · USGeorgetown University · USSt. Jude Children's Research Hospital · USUniversity of Florida · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI KUNLE ODUNSI · 1985 to 2026
$122.1M
NCI NIH HHS P30 CA014599NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundRacial/ethnic survival disparities in neuroblastoma were first reported more than a decade ago. We sought to investigate if these disparities have persisted with current era therapy.

methodsTwo patient cohorts were identified in the International Neuroblastoma Risk Group Data Commons (INRGdc) (Cohort 1: diagnosed 2001-2009, n=4359; Cohort 2: diagnosed 2010-2019, n=4891). Chi-squared tests were used to assess the relationship between race/ethnicity and clinical and biologic features. Survival was estimated by the Kaplan-Meier method. Cox proportional hazards regression analyses were performed to investigate the association between racial/ethnic groups and prognostic markers.

resultsSignificantly higher 5-year event-free survival (EFS) and overall survival (OS) were observed for Cohort 2 compared to Cohort 1 (P<0.001 and P<0.001, respectively). Compared to White patients, Black patients in both cohorts had a higher proportion of high-risk disease (Cohort 1: P<0.001; Cohort 2: P<0.001) and worse EFS (Cohort 1: P<0.001; Cohort 2 P<0.001) and OS (Cohort 1: P<0.001; Cohort 2: P<0.001). In Cohort 1, Native Americans also had a higher proportion of high-risk disease (P=0.03) and inferior EFS/OS. No significant survival disparities were observed for low- or intermediate-risk patients in either cohort or high-risk patients in Cohort 1. Hispanic patients with high-risk disease in Cohort 2 had significantly inferior OS (P=0.047). Significantly worse OS, but not EFS, (P=0.006 and P=0.02, respectively) was also observed among Black and Hispanic patients assigned to receive post-Consolidation dinutuximab on clinical trials (n=885).

conclusionRacial/ethnic survival disparities have persisted over time and were observed among high-risk patients assigned to receive post-Consolidation dinutuximab.

Indexed as

disparitiesethnicityneuroblastomaRace

Identifiers

PMID38213818
PMCPMC10783478
OpenAlexW4384926465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.